首页> 外文期刊>Chinese Journal of Contemporary Neurology and Neurosurgery >Influence of berberine combining with atorvastatin on serum high-sensitivity C-reactive protein and adipocyte fatty acid-binding protein in patients with acute ischemic stroke
【24h】

Influence of berberine combining with atorvastatin on serum high-sensitivity C-reactive protein and adipocyte fatty acid-binding protein in patients with acute ischemic stroke

机译:用阿托伐他汀与阿托伐他汀对急性缺血性卒中患者血清高灵敏度C反应蛋白和脂肪细胞脂肪酸结合蛋白的影响

获取原文
           

摘要

Objective To observe the influence of berberine combining with atorvastatin on serum high-sensitivity C-reactive protein (hs-CRP) and adipocyte fatty acid-binding protein (A-FABP) in patients with acute ischemic stroke. Methods Ischemic stroke patients (N = 55) were randomized into 3 groups: atorvastatin 20 mg/d (N = 28), atorvastatin 40 mg/d (N = 11) and berberine 0.40 g three times a day + atorvastatin 20 mg/d (combined treatment, N = 16). They were treated for 3 months. The expression changes of serum hs-CRP and A-FABP before and after treatment were compared among 3 groups. Results There were significant decreases between before and 3 months after treatment on the expression of hs-CRP and A-FABP in 3 groups (P = 0.023, 0.000). After treatment, both the expression of hs-CRP and A-FABP significantly decreased, and the decreases were (1.69 ± 2.29) and (281.43 ± 311.05) mg/L in atorvastatin 20 mg/d group, (7.81 ± 12.48) and (321.59 ± 289.35) mg/L in atorvastatin 40 mg/d group, and (2.16 ± 3.34) and (376.55 ± 249.72) mg/L in combined treatment group. However, there was no significant?difference among 3 groups (P > 0.05, for all), and there was no correlation between drugs and observation time points (P > 0.05, for all). Conclusions The effect of berberine combined with atorvastatin on hs-CRP and A-FABP is similar to atorvastation (40 mg/d) therapy.?DOI: 10.3969/j.issn.1672-6731.2015.01.010.
机译:目的观察小檗碱与阿托伐他汀对急性缺血性卒中患者血清高灵敏度C反应蛋白(HS-CRP)和脂肪细胞脂肪酸结合蛋白(A-FABP)的影响。方法将缺血性脑卒中患者(n = 55)随机分为3组:阿托伐他汀20mg / d(n = 28),阿托伐他汀40mg / d(n = 11)和小檗碱0.40g每日三次+阿托伐他汀20 mg / d (组合治疗,n = 16)。他们被治疗了3个月了。在3组中比较了治疗前后血清HS-CRP和A-FABP的表达变化。结果在3组中HS-CRP和A-FABP的表达后和3个月之间存在显着降低(P = 0.023,0.000)。治疗后,HS-CRP的表达和A-FABP的表达显着降低,降低(1.69±2.29)和(281.43±311.05)Mg / L在阿托伐他汀20 mg / d组,(7.81±12.48)和( 321.59±289.35)Mg / L在阿托伐他汀40 mg / d组,(2.16±3.34)和(376.55±249.72)Mg / L组合治疗组。然而,没有显着?3组之间的差异(P> 0.05,适用于所有),药物与观察时间点之间没有相关性(P> 0.05,全部)。结论小檗碱联合阿托伐他汀对HS-CRP和FABP的影响与非物质(40 mg / d)治疗类似。:10.3969 / J.issn.1672-6731.2015.01.010。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号